{"disease":{"id":"haematologic-neoplasm","name":"haematologic neoplasm"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06402175","title":"Characteristics and Outcomes of Patients With Hematological Malignancies","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":100,"lead_sponsor_name":"Assiut University","has_results":false},{"nct_id":"NCT07064122","title":"A Study of AZD2962, an IRAK4 Inhibitor (IRAK4 [a Body Protein] Blocker), in Participants With Haematologic Neoplasms (Blood Cancers)","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":72,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT06102876","title":"Feasibility of Physical Activity in Older Adults With Haematological Malignancies: ACCES Study","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":69,"lead_sponsor_name":"University Hospital, Toulouse","has_results":false},{"nct_id":"NCT05581875","title":"A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":48,"lead_sponsor_name":"Hellenic Society of Hematology","has_results":false},{"nct_id":"NCT05635591","title":"KSD-101 Therapy for EBV-associated Haematologic Neoplasms: an Exploratory Clinical Trial","phase":"PHASE1","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":9,"lead_sponsor_name":"Tongji Hospital","has_results":false}],"total":5},"guidelines":[],"source":"Drug Landscape verified database"}